CEPI (Coalition for Epidemic Preparedness Innovations)
Kenneth iyvehobu is an accomplished academic and research professional currently serving as a Lecturer at Ambrose Alli University since August 2023. In addition to this role, Kenneth has been involved with the Coalition for Epidemic Preparedness Innovations (CEPI) as a Data Collector and Data Analyst since December 2020. As Chief Researcher and Research Scientist at St Kenny Consult since May 2015, Kenneth has contributed significantly to various research projects. Previous experience includes working as a Medical Laboratory Scientist at Clina-Lancet Laboratories from December 2018 to November 2019 and managing Eseohe Medical Centre as both a Medical Laboratory Scientist and Manager from April 2012 to April 2016. Kenneth holds a Master's degree in Public Health from the National Open University of Nigeria and a Bachelor's degree in Clinical/Medical Laboratory Science from Ambrose Alli University.
This person is not in any teams
This person is not in any offices
CEPI (Coalition for Epidemic Preparedness Innovations)
2 followers
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net